scholarly journals Faculty Opinions recommendation of Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

2017 ◽  
Author(s):  
Varsha Gandhi ◽  
Prithviraj Bose
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Highly Active ◽  
Cd20 Antibody ◽  
Anti Cd20

Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia

2021 ◽  
Vol 14 (12) ◽  
pp. e245557
Author(s):  
Oday Elmanaseer ◽  
Alzira R M Avelino ◽  
Amin Azem ◽  
Mihir Raval
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Effective Treatment ◽  
Inflammatory Markers ◽  
Lymphocytic Leukaemia ◽  
Maculopapular Rash ◽  
Serum Sickness ◽  
Rare Entity ◽  
Cd20 Antibody ◽  
Anti Cd20

Serum sickness (SS) is a known phenomenon; however, it is commonly missed due to vague symptoms, and is usually confounded by other aetiologies that present similarly. Obinutuzumab is a novel anti-CD20 antibody agent that has been approved for chronic lymphocytic leukaemia (CLL) treatment. At the time of approval, it was not linked to SS; however, this phenomenon has been recognised with other anti-CD20 agents like rituximab. SS remains a rare entity, but it is important to be recognised accurately and quickly in the appropriate circumstances, so that effective treatment with corticosteroids can be initiated to alleviate inflammatory symptoms. Here we present a patient with CLL who developed maculopapular rash, fever and polyarthritis and elevated inflammatory markers consistent with serum sickness triggered by obinutuzumab and was effectively treated with corticosteroids.

scholarly journals Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

2018 ◽  
Vol 5 (4) ◽  
pp. e170-e180 ◽  
Author(s):  
Jennifer R Brown ◽  
Mehdi Hamadani ◽  
John Hayslip ◽  
Ann Janssens ◽  
Nina Wagner-Johnston ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Open Label Phase

Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial

2016 ◽  
Vol 3 (9) ◽  
pp. e407-e414 ◽  
Author(s):  
Paolo Strati ◽  
Mark Lanasa ◽  
Timothy G Call ◽  
Jose F Leis ◽  
Danielle M Brander ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Phase 2 Trial

scholarly journals Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

2017 ◽  
Vol 4 (2) ◽  
pp. e67-e74 ◽  
Author(s):  
Preetesh Jain ◽  
Michael Keating ◽  
Sarah Renner ◽  
Charles Cleeland ◽  
Huang Xuelin ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Symptom Control ◽  
Phase 2 ◽  
Single Group ◽  
Phase 2 Trial

scholarly journals Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

2014 ◽  
Vol 165 (5) ◽  
pp. 731-733 ◽  
Author(s):  
Christine I. Chen ◽  
Harminder Paul ◽  
Trina Wang ◽  
Lisa W. Le ◽  
Nimisha Dave ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Single Agent ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document